ASX-Dividend-Report-Banner

Opioids kill 3 Aussies a day - while fewer than 5% of doctors prescribe medical cannabis

February 12, 2024 03:17 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Opioids kill 3 Aussies a day - while fewer than 5% of doctors prescribe medical cannabis
Image source: Kalkine Media

MELBOURNE, Australia, Feb. 12, 2024 /PRNewswire/ -- A recent survey by Alternaleaf, Australia's largest medical cannabis clinic, has revealed that 80% of Australian patients want more doctors to prescribe medical cannabis.

An estimated 5% of Australian doctors prescribe medical cannabis[1] - even though Alternaleaf survey data has found that 62% of patients stopped taking other pain medication after starting medical cannabis treatment[2]

Though recent statistics indicate that three people a day die from drug-induced deaths involving opioid use[3], many Alternaleaf patients found that their general practitioners were unwilling to even discuss the prospect of prescribing medical cannabis. 

"My doctor told me he wouldn't prescribe it," said Mei*. 

"He refused to even say the word." 

For Hunter*, the journey to finding a viable form of pain relief has been harder than most. 

"I have a high tolerance to opioids after being on them for twenty years to treat my chronic pain," he explained. 

"My doctor recommended opioid pain relief alongside my antidepressants, but all it did was make me put on weight, which made my chronic pain worse. When I tried talking to several doctors about medical cannabis as an option, all they did was shrug off my suggestions and suggest a different opioid. 

"Since being on medical cannabis, I don't use my opioids as much, and I'm not seeing a doctor every two weeks for a new script - I also don't get side effects from it."

Rhys Staley, Vice President of Montu, the parent company of Alternaleaf, has urged doctors to consider prescribing medical cannabis to eligible patients. 

"Every day, Alternaleaf doctors see patients who have benefited from making the switch to medical cannabis," Staley said.

"If more doctors were as comfortable prescribing medical cannabis as they are opioid and other pharmaceutical medication for pain relief, Australian patients wouldn't have to suffer unnecessarily when looking for alternatives. 

"Clinical education should encompass the full range of pain relief medication, so that medical professionals can offer an array of treatment options to find the best fit for their patients' needs." 

For more information, visit montu.com.au.

*Patient names changed for privacy reasons.

About Alternaleaf
Alternaleaf is Australia's largest medical cannabis clinic, trusted by more than 100,000 Australians. Connecting patients with highly trained nurses and doctors through an innovative telehealth system, Alternaleaf prides itself on its easy-to-use and empathetic clinical experience.

About Montu

Founded in 2019, Montu is Australia's leading medical cannabis company. Across a rapidly growing ecosystem, Montu is using technology to improve the medical cannabis patient experience, from delivering best-in-class clinical care, to our industry-leading product lines and innovative supply chain management tools. Our mission: to make medical cannabis more affordable and accessible for the millions who could benefit.

Contact

For more information or interview opportunities, please contact:

Maggie Kerr - Communications Advisor
[email protected]
0457 097 772

[1] Comparison of SAS-B TGA Authorised Prescriber and Department of Health and Aged Care data
[2] Data compiled from more than 3000 Alternleaf patient responses to an August 2023 survey about chronic pain
[3] Australian Institute of Health and Welfare


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.